-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Lumos Pharma, Inc. (NASDAQ:LUMO) CEO Purchases $19,571.76 in Stock
Lumos Pharma, Inc. (NASDAQ:LUMO) CEO Purchases $19,571.76 in Stock
Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) CEO Richard J. Hawkins bought 2,214 shares of the business's stock in a transaction that occurred on Wednesday, September 21st. The stock was purchased at an average cost of $8.84 per share, with a total value of $19,571.76. Following the purchase, the chief executive officer now directly owns 4,261 shares in the company, valued at approximately $37,667.24. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Lumos Pharma Trading Up 0.9 %
Shares of NASDAQ LUMO traded up $0.08 on Friday, reaching $9.00. 10,536 shares of the company traded hands, compared to its average volume of 16,147. The company has a 50 day moving average of $8.35 and a 200 day moving average of $8.29. Lumos Pharma, Inc. has a fifty-two week low of $6.15 and a fifty-two week high of $10.73.
Get Lumos Pharma alerts:Lumos Pharma (NASDAQ:LUMO – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.98) by $0.04. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.11 million. As a group, equities analysts predict that Lumos Pharma, Inc. will post -3.82 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. Oppenheimer assumed coverage on shares of Lumos Pharma in a research note on Tuesday, July 19th. They set an "outperform" rating and a $20.00 price objective for the company. Roth Capital reaffirmed a "buy" rating on shares of Lumos Pharma in a research note on Tuesday, August 9th.Hedge Funds Weigh In On Lumos Pharma
Institutional investors and hedge funds have recently bought and sold shares of the stock. Urban Wealth Management LLC purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $27,000. Envestnet Asset Management Inc. purchased a new position in shares of Lumos Pharma during the 4th quarter valued at approximately $72,000. Key Financial Inc purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $84,000. Opaleye Management Inc. purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $166,000. Finally, Private Advisor Group LLC purchased a new position in shares of Lumos Pharma during the 1st quarter valued at approximately $263,000. Hedge funds and other institutional investors own 28.36% of the company's stock.
About Lumos Pharma
(Get Rating)
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
Read More
- Get a free copy of the StockNews.com research report on Lumos Pharma (LUMO)
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) CEO Richard J. Hawkins bought 2,214 shares of the business's stock in a transaction that occurred on Wednesday, September 21st. The stock was purchased at an average cost of $8.84 per share, with a total value of $19,571.76. Following the purchase, the chief executive officer now directly owns 4,261 shares in the company, valued at approximately $37,667.24. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
卢莫斯制药公司(纳斯达克代码:Lumo-Get评级)首席执行官理查德·J·霍金斯在9月21日星期三的一笔交易中购买了2214股卢莫斯制药公司的股票。这只股票是以每股8.84美元的平均价格购买的,总价值为19571.76美元。收购完成后,这位首席执行官现在直接拥有该公司4261股,价值约37,667.24美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过此超链接.
Lumos Pharma Trading Up 0.9 %
Lumos Pharma股价上涨0.9%
Shares of NASDAQ LUMO traded up $0.08 on Friday, reaching $9.00. 10,536 shares of the company traded hands, compared to its average volume of 16,147. The company has a 50 day moving average of $8.35 and a 200 day moving average of $8.29. Lumos Pharma, Inc. has a fifty-two week low of $6.15 and a fifty-two week high of $10.73.
上周五,纳斯达克LUMO的股价上涨0.08美元,达到9.00美元。该公司有10,536股易手,而其平均成交量为16,147股。该公司的50日移动均线切入位在8.35美元,200日移动均线切入位在8.29美元。Lumos Pharma,Inc.的股价为6.15美元,为52周低点,52周高点为10.73美元。
Lumos Pharma (NASDAQ:LUMO – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.98) by $0.04. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.11 million. As a group, equities analysts predict that Lumos Pharma, Inc. will post -3.82 earnings per share for the current year.
Lumos Pharma(纳斯达克代码:Lumo-Get评级)最近一次公布财报是在8月9日(星期二)。该公司公布本季度每股收益(EPS)为0.94美元,比分析师普遍预期的每股收益(0.98美元)高出0.04美元。该业务本季度营收为40万美元,而分析师预期为11万美元。作为一个整体,股票分析师预计Lumos Pharma,Inc.本年度每股收益将达到3.82美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Hedge Funds Weigh In On Lumos Pharma
对冲基金参与Lumos Pharma
Institutional investors and hedge funds have recently bought and sold shares of the stock. Urban Wealth Management LLC purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $27,000. Envestnet Asset Management Inc. purchased a new position in shares of Lumos Pharma during the 4th quarter valued at approximately $72,000. Key Financial Inc purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $84,000. Opaleye Management Inc. purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $166,000. Finally, Private Advisor Group LLC purchased a new position in shares of Lumos Pharma during the 1st quarter valued at approximately $263,000. Hedge funds and other institutional investors own 28.36% of the company's stock.
机构投资者和对冲基金最近买卖了该股的股票。Urban Wealth Management LLC在第二季度购买了Lumos Pharma的新头寸,价值约2.7万美元。Envestnet资产管理公司在第四季度购买了Lumos Pharma公司新的股票头寸,价值约7.2万美元。Key Financial Inc.在第二季度购买了Lumos Pharma的新头寸,价值约8.4万美元。Opalye Management Inc.在第二季度购买了Lumos Pharma公司新的股票头寸,价值约为16.6万美元。最后,私人顾问集团LLC在第一季度购买了Lumos Pharma公司价值约26.3万美元的新股票头寸。对冲基金和其他机构投资者持有该公司28.36%的股票。
About Lumos Pharma
关于Lumos Pharma
(Get Rating)
(获取评级)
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
Lumos制药公司是一家临床阶段的生物制药公司,专注于罕见疾病治疗药物的开发和商业化。它的主要候选治疗药物Lum-201是一种口服生长激素促分泌剂布洛莫伦,该药正处于第二阶段临床试验,用于治疗儿童生长激素缺乏症和其他罕见的内分泌疾病。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Lumos Pharma (LUMO)
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 免费获取StockNews.com关于Lumos Pharma的研究报告(LUMO)
- 为什么特斯拉的股票保持弹性?
- 好市多盈利后价格疲软是买入的好时机吗?
- 需要关注的2只半导体类股走势逆转
- 小盘股的裁员是楼市的晴雨表吗?
- CrowdStrike是否会从增加每股收益指引中获得提振?
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受Lumos Pharma Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收Lumos Pharma和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧